The first patient is an important milestone in any clinical trial. In our CRUZ-SENIOR study, Prof. Dr. David M. Leistner and his study team from Charité Universitätsmedizin Berlin succeeded in initiating patient enrolment. The CRUZ-SENIOR study focuses on the treatment of the complex, steadily growing cohort of octogenarian and ninety-year-old patients who have been treated with a Supraflex Cruz stent. This represents one of the most complex high-risk patient cohorts for percutaneous coronary intervention in daily clinical practice. The IHF GmbH team wishes the first and all following patients a fast recovery and good health with a high quality of life.